Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis

Daryabeygi-Khotbehsara, Reza; Golzarand, Mahdieh; Ghaffari, Mohammad Payam; Djafarian, Kurosh

doi:10.1016/j.ctim.2017.08.016

Cited by 79 publications

(95 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous meta‐analysis revealed that N . sativa had beneficial effects in type 2 diabetes (Daryabeygi‐Khotbehsara et al, ). Although the results of mentioned study are partially similar to our meta‐analysis, some differences should be discussed.…”

Section: Discussionmentioning

confidence: 99%

“…Previous meta-analysis revealed that N. sativa had beneficial effects in type 2 diabetes (Daryabeygi-Khotbehsara et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…In a previous meta‐analysis, one limited number of trials revealed that N . sativa had beneficial effects on glycosylated hemoglobin and blood glucose in subjects with type 2 diabetes (Daryabeygi‐Khotbehsara, Golzarand, Ghaffari, & Djafarian, ).…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that N. sativa may play a role in activation of insulin secretion, reduction in oxidant agents, and inhibition of hepatic gluconeogenesis (Fararh et al, 2004;Fararh, Atoji, Shimizu, & Takewaki, 2002;Kanter, Meral, Yener, Ozbek, & Demir, 2003). In a previous meta-analysis, one limited number of trials revealed that N. sativa had beneficial effects on glycosylated hemoglobin and blood glucose in subjects with type 2 diabetes (Daryabeygi-Khotbehsara, Golzarand, Ghaffari, & Djafarian, 2017).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta‐analysis of clinical trials

Askari

Rouhani

Ghaedi

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

This study was aimed to quantify the antihyperglycemic effect of Nigella sativa (N. sativa). An in‐depth search to identify clinical trials investigating the impact of N. sativa on glycemic indices via MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Library, and Google scholar databases were performed up to November 2018. We used a random effects model to estimate pooled effect size of fasting plasma glucose (FPG), postprandial blood glucose (PPBG), and hemoglobin A1c (HbA1c). A total of 17 randomized controlled trials investigating the effects of N. sativa on FPG, PPBG, and HbA1c were included. Meta‐analysis suggested a significant association between N. sativa supplementation and reduction in FPG (weighted mean difference [WMD]: −9.93 mg/dl, 95% CI [−13.44, −6.41]), PPBG (WMD: −14.79 mg/dl, 95% CI [−24.19, −5.39]), and HbA1c (WMD: −0.57%, 95% CI [−0.77, −0.37]). Subgroup analysis revealed that N. sativa oil was more effective than N. sativa powder in reduction of FPG. To sum up, N. sativa consumption has a significant lowering effect on glycemic status. Further studies with prolonged durations and powerful design are needed to specify the exact mechanism, optimal dosage, and duration of N. sativa supplementation to obtain a beneficial effect on glycemic status.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previous meta-analysis revealed that N. sativa had beneficial effects in type 2 diabetes (Daryabeygi-Khotbehsara et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta‐analysis of clinical trials

Askari

Rouhani

Ghaedi

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Gemäß einem systematischen Review mit Metaanalyse aus 7 Studien nahmen unter der Zufuhr von Zubereitungen aus dem Schwarzkümmel der mittlere Nüchtern-Blutzucker um 18 mg / dl und das glykierte Hämoglobin (HbA 1c ) um etwa 1 % (absolut) ab. Das Gesamtcholesterin hatte um 23 mg / dl und das LDL-Cholesterin um 22 mg / dl abgenommen [6]. Unter der Einnahme von 2 g / d Samenpulver über ein Jahr nahmen auch die erhöhte Insulinresistenz und die Thiobarbitursäure-reaktiven Substanzen im Serum ab.…”

Section: Diabetes Mellitus Und Hyperlipidämieunclassified

Schwarzkümmel: Medizin-Tipp aus der Bibel

Vlachojannis

Chrubasik‐Hausmann

2019

Z Phytother

View full text Add to dashboard Cite

ZusammenfassungIn zusammenführenden Studien senkte Schwarzkümmel das Gewicht, den erhöhten Nüchtern-Blutzucker und das glykierte Hämoglobin (HbA1c) und erhöhte die Ansprechbarkeit auf Insulin. Die Blutfette und der Blutdruck nahmen ab. Jetzt müssen Studien mit einem beweisenden Studiendesign die Wirkgrößen bei Typ-2-Diabetes, Hyperlipidämie und Bluthochdruck bestätigen und prüfen, ob Zubereitungen aus Schwarzkümmel das kardiovaskuläre Risiko senken. Vielversprechend sind die Ergebnisse der Studien bei Patienten mit rheumatoider Arthritis, Hashimoto-Thyreoiditis und Vitiligo, die Wirksamkeit bei Autoimmunerkrankungen demonstrieren. Studien bei Patienten mit Asthma bronchiale, Heuschnupfen und atopischem Ekzem weisen auf eine antiasthmatische und antiallergische Wirkung des Schwarzkümmel-Wirkstoffs hin. Durch die antibakterielle Wirkung lassen sich Antibiotika einsparen. Die Studienlage bei Nierensteinen, Organerkrankungen und toxischer Organschädigung, Arthrose, Kindern mit epileptischen Anfällen, Dyspepsie, klimakterischen Beschwerden, rezidivierender Mastalgie und neurodegenerativen Erkrankungen ist unzureichend. Die Tagesdosis beträgt bis zu 3 g Samen oder Samenöl. Die Verträglichkeit ist gut. Wechselwirkungen mit anderen Medikamenten sind nicht ausreichend untersucht.

show abstract

Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats

Adiwidjaja

Sasongko

2021

Biopharm & Drug Disp

View full text Add to dashboard Cite

Nigella sativa oil (NSO) has been used widely for its putative anti‐hyperglycemic activity. However, little is known about its potential effect on the pharmacokinetics and pharmacodynamics of antidiabetic drugs, including gliclazide. This study aimed to investigate herb–drug interactions between gliclazide and NSO in rats. Plasma concentrations of gliclazide (single oral and intravenous dose of 33 and 26.4 mg/kg, respectively) in the presence and absence of co‐administration with NSO (52 mg/kg per oral) were quantified in healthy and insulin resistant rats (n = 5 for each group). Physiological and treatment‐related factors were evaluated as potential influential covariates using a population pharmacokinetic modeling approach (NONMEM version 7.4). Clearance, volume of distribution and bioavailability of gliclazide were unaffected by disease state (healthy or insulin resistant). The concomitant administration of NSO resulted in higher systemic exposures of gliclazide by modulating bioavailability (29% increase) and clearance (20% decrease) of the drug. A model‐independent analysis highlighted that pre‐treatment with NSO in healthy rats was associated with a higher glucose lowering effect by up to 50% compared with that of gliclazide monotherapy, but not of insulin resistant rats. Although a similar trend in glucose reductions was not observed in insulin resistant rats, co‐administration of NSO improved the sensitivity to insulin of this rat population. Natural product–drug interaction between gliclazide and NSO merits further evaluation of its clinical importance.

show abstract

Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis

Cited by 79 publications

References 32 publications

Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta‐analysis of clinical trials

Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta‐analysis of clinical trials

Schwarzkümmel: Medizin-Tipp aus der Bibel

Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats

Contact Info

Product

Resources

About